Larimar Therapeutics, Inc. (LRMR)
$4.09
-0.07 (-1.68%)
Rating:
Recommendation:
-
| Symbol | LRMR |
|---|---|
| Price | $4.09 |
| Beta | 0.215 |
| Volume Avg. | 0.26M |
| Market Cap | 177.005M |
| Shares () | - |
| 52 Week Range | 2.58-6.85 |
| 1y Target Est | - |
| DCF Unlevered | LRMR DCF -> | |
|---|---|---|
| DCF Levered | LRMR LDCF -> | |
| ROE | -27.83% | Sell |
| ROA | -27.14% | Sell |
| Operating Margin | - | |
| Debt / Equity | 5.08% | Neutral |
| P/E | -5.60 | Strong Sell |
| P/B | 1.80 | Strong Buy |
Latest LRMR news
About
Download (Excel)Dr. Carole S. Ben-Maimon M.D.
Healthcare
Biotechnology
NASDAQ Global Market
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.